Joseph B. Mandeville

Robust changes in brain function require high D2 receptor occupancy by prochlorperazine: an imaging correlate for the antipsychotic therapeutic window

Abstract The dopamine D 2 -receptor antagonist prochlorperazine is approved clinically as both an antipsychotic and an antiemetic. Classical antipsychotics like prochlorperazine have been shown to treat the positive symptoms of schizophrenia at occupancies higher than 60% with ex...